Regulus Therapeutics Inc. (RGLS)
Jun 25, 2025 - RGLS was delisted (reason: acquired by Novartis)
8.16
+0.02 (0.25%)
Inactive · Last trade price on Jun 24, 2025
Regulus Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Regulus Therapeutics stock had an average target of 8.50, with a low estimate of 7.00 and a high estimate of 11.
Price Target: $8.50 (+4.17%)
Analyst Consensus: Buy
* Price targets were last updated on May 1, 2025.
Analyst Ratings
The average analyst rating for Regulus Therapeutics stock from 6 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 1 | 1 |
| Hold | 1 | 1 | 0 | 3 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 5 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $9 | Buy → Hold | Downgrades | $9 | +10.29% | May 1, 2025 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $7 | Buy → Hold | Downgrades | $7 | -14.22% | Apr 30, 2025 |
| Jones Trading | Jones Trading | Strong Buy → Hold Downgrades $8 → $7 | Strong Buy → Hold | Downgrades | $8 → $7 | -14.22% | Apr 30, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades $28 → $11 | Strong Buy → Hold | Downgrades | $28 → $11 | +34.80% | Apr 30, 2025 |
| Wells Fargo | Wells Fargo | Hold → Buy Upgrades $3 → $6 | Hold → Buy | Upgrades | $3 → $6 | -26.47% | Mar 27, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-0.92
from -0.82
EPS Next Year
-1.08
from -0.92
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | 185.6M | ||
| Avg | n/a | n/a | 90.2M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.74 | -0.82 | 0.84 | ||
| Avg | -0.92 | -1.08 | -0.12 | ||
| Low | -1.12 | -1.24 | -1.02 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.